Cash and cash equivalents (USD, thousands)

Short-term investments (USD, thousands)

Accounts receivable, net (USD, thousands)

Inventory (USD, thousands)

Prepaid expenses and other current assets (USD, thousands)

Total current assets (USD, thousands)

Property and equipment, net (USD, thousands)

Operating lease right-of-use assets (USD, thousands)

Other assets (USD, thousands)

Total assets (USD, thousands)

Accounts payable (USD, thousands)

Accrued liabilities (USD, thousands)

Operating lease liabilities, current portion (USD, thousands)

Due to licensor payable (USD, thousands)

Total current liabilities (USD, thousands)

Operating lease liabilities, net of current portion (USD, thousands)

Other liabilities (USD, thousands)

Total liabilities (USD, thousands)

Common stock (USD, thousands)

Additional paid-in capital (USD, thousands)

Accumulated other comprehensive income (USD, thousands)

Accumulated deficit (USD, thousands)

Total stockholders’ equity (USD, thousands)

Total liabilities and stockholders’ equity (USD, thousands)

ffd90d5938d22e354fa1d1119645aa295b7e753b1e4daabd7bb983dee3ec41cb

Product Sales, Net (USD, thousands)

Total Revenue (USD, thousands)

Selling, General and Administrative Expenses (USD, thousands)

Research and Development Expenses (USD, thousands)

Cost of Goods Sold (USD, thousands)

Total Operating Expenses (USD, thousands)

Loss from Operations (USD, thousands)

Foreign Exchange Loss (USD, thousands)

Interest Income (USD, thousands)

Interest Expense (USD, thousands)

Total Other Income (Expense), Net (USD, thousands)

Loss Before Income Tax Expense (USD, thousands)

Income Tax Expense (USD, thousands)

Net Loss (USD, thousands)

Change in Unrealized Loss on Short-Term Investments (USD, thousands)

Comprehensive Loss (USD, thousands)

Net Loss per Share, Basic and Diluted (USD)

Weighted Average Number of Common Shares Outstanding, Basic and Diluted

1129f7b960a8adfaa346cdcab2f1418fea14e533c60ca947623829d2733c1a3e

Net loss (USD, thousands)

Share-based compensation expense (USD, thousands)

Amortization of premiums and discounts on short-term investments, net (USD, thousands)

Non-cash interest expense (USD, thousands)

Non-cash lease expense (USD, thousands)

Depreciation and amortization expense (USD, thousands)

Net cash used in operating activities (USD, thousands)

Purchases of property and equipment (USD, thousands)

Purchase of short-term investments (USD, thousands)

Maturity of short-term investments (USD, thousands)

Net cash provided by (used in) investing activities (USD, thousands)

Issuance of common stock upon exercise of stock options (USD, thousands)

Proceeds from issuance of common stock under employee stock purchase plan (USD, thousands)

Deferred offering costs paid for financing (USD, thousands)

Net cash provided by financing activities (USD, thousands)

Net increase (decrease) in cash, cash equivalents and restricted cash (USD, thousands)

Interest paid during the period (USD, thousands)

Cash, cash equivalents and restricted cash, beginning of year (USD, thousands)

Cash, cash equivalents and restricted cash, end of period (USD, thousands)

100540e00b7bb93b27309d4a8067381539336675603a61c09813e91a4e553065

Current Assets (USD, thousands)

Cash and Cash Equivalents (USD, thousands)

Accounts Receivable (USD, thousands)

Non-Current Assets (USD, thousands)

Property, Plant, and Equipment (PP&E) (USD, thousands)

Current Liabilities (USD, thousands)

Accounts Payable (USD, thousands)

Accrued Expenses (USD, thousands)

Shareholders' Equity (USD, thousands)

Retained Earnings (USD, thousands)

Common Stock (USD, thousands)

Additional Paid-in Capital (USD, thousands)

de7a4164b5e60c1364d14fe97c11d650e14c8c074d7ae980aac69ba3274b7d37

Number of patients enrolled in Phase 2 advanced or recurrent endometrioid-type endometrial cancer (EEC) trial (patients)

Number of patients enrolled in Phase 2 advanced or recurrent neuroendocrine tumors (NET) trial (patients)

7ad7863c1efd21000caac4b18d3f573b8d77ce0d84d5fbe62e394b79b8720294

Cost of Goods Sold (COGS) (USD, thousands)

Selling, General, and Administrative Expenses (SG&A) (USD, thousands)

Research and Development (R&D) (USD, thousands)

Depreciation and Amortization (D&A) (USD, thousands)

Operating Income (EBIT) (USD, thousands)

Net Income (USD, thousands)

Earnings Per Share (EPS) - Basic (USD)

Earnings Per Share (EPS) - Diluted (USD)

2de93d1ac73bc20e348efbf9cb0dc7b8b42da00e7682b1477f0c58562ffdef19

Adjustments for Non-Cash Items (USD, thousands)

Stock-Based Compensation (USD, thousands)

Changes in Working Capital (USD, thousands)

Capital Expenditures (CapEx) (USD, thousands)

Proceeds from / Repayments of Debt (USD, thousands)

Share Repurchases (USD, thousands)

Dividend Payments (USD, thousands)

Net Change in Cash (USD, thousands)

8dbd726c7f08b8a9569bc50147089701bd4d4405391337d85024fad019b03666

Product Sales, Net

License Revenue

Grant Revenue

Total Revenue

62c84453ac7fe667de28713ccf26cb7c34d4d5a1bb5daca34c943698368879c5

Company not found (AADI)

Financials